AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024Lausanne, Switzerland, July 31, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC (Morphomer® Antibody Drug Conjugate) in an oral presentation at the annual Alzheimer’s Association International Conference (AAIC 2024), taking place from July 28 – August 1, 2024, in Philadelphia, PA.Dr.

AC Immune于2024年7月31日在瑞士洛桑AAIC 2024Lousanne推出了一种新的治疗性抗体-药物偶联物（ADC）技术，以提高神经退行性疾病的疗效。AC Immune SA（纳斯达克：ACIU）是一家临床阶段的生物制药公司，开创了神经退行性疾病的精准医学，今天在2024年7月28日至8月1日在宾夕法尼亚州费城举行的年度阿尔茨海默病协会国际会议（AAIC 2024）上，在口头介绍中推出了一类新型的抗神经退行性疾病候选药物morADC（Morphomer®抗体-药物偶联物）。

Madiha Derouazi, Chief Scientific Officer of AC Immune, presented the characterization and in vitro efficacy of morADC for the first time. The talk, entitled “A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer®- Antibody Drug Conjugates)”, showed that:While in oncology antibody-drug conjugates are designed to selectively kill tumor cells in a targeted manner, AC Immune’s morADC for neurodegenerative diseases combine the high brain penetrance of Morphomer small molecules with the target specificity of monoclonal antibodies, to reduce pathological, aggregating proteins in the central nervous system.Dr.

AC Immune首席科学官Madiha Derouazi首次介绍了morADC的表征和体外功效。这篇题为“一类新的抗神经退行性疾病药物：morADC（Morphomer®-抗体-药物偶联物）”的演讲表明：虽然在肿瘤学中，抗体-药物偶联物旨在以靶向方式选择性杀死肿瘤细胞，但AC Immune的神经退行性疾病morADC将Morphomer小分子的高脑渗透性与单克隆抗体的靶向特异性结合起来，以减少中枢神经系统中的病理性聚集蛋白。博士。

Andrea Pfeifer, CEO of AC Immune SA, commented: “Today we unveil our powerful new morADC technology, which synergistically combines the industry-leading capabilities of our SupraAntigen and Morphomer platforms. Based on the data we have produced to date, we are confident that this is a groundbreaking moment, showing that morADC offer unique functionality and are potentially disruptive in our industry.

AC Immune SA首席执行官Andrea Pfeifer评论道：“今天，我们推出了强大的新morADC技术，该技术协同结合了我们的超抗原和形态异构体平台的业界领先功能。根据我们迄今为止产生的数据，我们相信这是一个开创性的时刻，表明morADC提供了独特的功能，并可能在我们的行业中产生破坏性。

We look forward with great enthusiasm to developing these exciting first-in-class therapeutic candidates as part of our mission to pioneer precisio.

我们怀着极大的热情期待着开发这些令人兴奋的一流治疗候选人，作为我们开创precisio使命的一部分。

Attachment

附件

Source: AC Immune SA

来源：AC Immune SA